Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study

BACKGROUND: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody administered with a 20 mg subcutaneous monthly dosing regimen. METHODS: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald crit...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Emanuele, Zanghì, Aurora, Fantozzi, Roberta, Centonze, Diego, Avolio, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2023
Materias:
Medicine, Neurology, Pharmacology, Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614110/
https://www.ncbi.nlm.nih.gov/pubmed/37534789
http://dx.doi.org/10.2174/1570159X21666230803161825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614110/
https://www.ncbi.nlm.nih.gov/pubmed/37534789
http://dx.doi.org/10.2174/1570159X21666230803161825

Ejemplares similares